A

Aurinia Pharmaceuticals
D

AUPH

8.07000
USD
-0.20
(-2.36%)
مغلق
حجم التداول
96,661
الربح لكل سهم
1
العائد الربحي
-
P/E
30
حجم السوق
1,090,291,717
أصول ذات صلة
A
ACAD
0.450
(2.09%)
21.990 USD
AMGN
AMGN
-0.04
(-0.01%)
271.89 USD
A
ARRY
-0.11500
(-1.64%)
6.88500 USD
C
CRIS
-0.01000
(-0.51%)
1.97000 USD
E
ESPR
-0.01830
(-2.27%)
0.78900 USD
MRK
MRK
-0.220
(-0.28%)
77.600 USD
V
VKTX
-0.715
(-2.58%)
26.985 USD
VRTX
VRTX
1.79
(0.41%)
435.79 USD
المزيد
الأخبار المقالات

العنوان: Aurinia Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmunediseases.